Gamida Cell (GMDA) Received its Third Buy in a Row


After H.C. Wainwright and Needham gave Gamida Cell (NASDAQ: GMDA) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Mark Breidenbach maintained a Buy rating on Gamida Cell today and set a price target of $20.00. The company’s shares closed last Thursday at $4.89.

According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 10.7% and a 46.5% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company.

Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $17.33, implying a 285.1% upside from current levels. In a report issued on May 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.

See today’s analyst top recommended stocks >>

Based on Gamida Cell’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.71 million. In comparison, last year the company had a GAAP net loss of $22.63 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Read More on GMDA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts